You are here

Iodide for the treatment of influenza and other stresses

Award Information
Agency: Department of Defense
Branch: Army
Contract: W911NF-22-C-0049
Agency Tracking Number: A2-9060
Amount: $1,099,873.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: A20B-T028
Solicitation Number: 20.B
Timeline
Solicitation Year: 2020
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-09-30
Award End Date (Contract End Date): 2024-09-29
Small Business Information
Fluke Hall Suite 304, 4000 Mason Road
Seattle, WA 98195-2141
United States
DUNS: 080831736
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Michael Morrison
 (206) 667-4318
 mmorriso@fredhutch.org
Business Contact
 Sami Kanaan
Phone: (206) 432-2736
Email: skanaan@chimerocyte.com
Research Institution
 Fred Hutchinson Cancer Research Center
 Mark Roth
 
1100 Fairview Ave N
Seattle, WA 98109-1024
United States

 (206) 667-5602
 Domestic Nonprofit Research Organization
Abstract

The goal of this work is to test the hypothesis that prophylactic administration of oral iodide reduces soldier and civilian mortality resulting from subsequent injury and infection while improving performance and readiness. In phase I we determined the blood levels of iodide in people that were subjected to Acute Mountain Sickness (AMS) due to rapid transition from sea level to 17,000 feet of elevation in 1 day and found that those with higher levels of blood iodide were more resistant to AMS. We also found that these people had increased VO2 max and hemoglobin content. To test whether increase blood iodide can cause increased survival from stress we conducted a lethal mouse model of viral respiratory infection and found that prophylactic administration of iodide in the diet both increased blood iodide levels and dramatically improved survival. We also found that this same increase in blood levels of iodide improved outcome from a mouse model of trauma. Based on these findings we propose in Phase II to do the necessary work required to file an investigational new drug application (IND) with the FDA necessary to begin clinical studies testing oral sodium iodide as a drug to treat influenza and further observational studies in soldiers that could form the foundation for additional indications for the use of our oral sodium iodide product.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government